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G protein-coupled receptorAgonist potency at some neurotransmitter receptors has been shown to be regulated by voltage, a mechanism
which has been suggested to play a crucial role in the regulation of neurotransmitter release by inhibitory
autoreceptors. Likewise, receptor deactivation rates upon agonist removal have been implicated in autoreceptor
function. UsingG protein-coupled potassium (GIRK) channel activation inXenopus oocytes as readout of receptor
activity, we have investigated the voltage sensitivities and signaling kinetics of the hH3445 and hH3365 isoforms of
the human histamine H3 receptor, which functions as an inhibitory auto- and heteroreceptor in the nervous
system. We have also investigated both the human and the mouse homologues of the related histamine H4
receptor, which is expressed mainly on hematopoietic cells. We found that the hH3445 receptor is the most
sensitive to voltage, whereas the hH3365 and H4 receptors are less affected. We further observed a marked
difference in response deactivation kinetics between the hH3
445 and hH3
365 isoforms, with the hH3
365 isoform
being ﬁve to six-fold slower than the hH3445 receptor. Finally, using synthetic agonists, we found evidence for
agonist-speciﬁc voltage sensitivity at the hH4 receptor. The differences in voltage sensitivities and deactivation
kinetics between the hH3445, hH3365, and H4 receptors might be relevant to their respective physiological roles.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The histamine H3 and H4 receptors are closely related Gi/o-coupled
receptors, and the most recently cloned of the four known human
histamine receptors. In view of the therapeutically important actions
of histamine H1 and H2 receptor ligands in the immune system and
the GI tract, as well as novel ﬁndings implicating H3 and H4 receptors in
CNS and immune functions as outlined below, these two novel histamine
receptors have attracted much interest as potential drug targets [1,2].
The histamine H3 receptor is expressed mainly within the nervous
system, predominantly at presynaptic sites, but also postsynaptically
in certain locations including the striatum [1,3]. Whereas originally
described as an inhibitory autoreceptor on histaminergic terminals
in the brain [4], the H3 receptor has also been found to function as a
heteroreceptor, regulating the release of a various neurotransmitters
including noradrenalin, serotonin, dopamine, and acetyl choline
[1]. The postsynaptic roles of the H3 receptor in the striatum include
inhibition of cAMP accumulation and modulation of dopamine recep-
tors via direct protein–protein interactions [5,6]. In agreement wither potassium channel; GPCR, G
ceptor; H3365, human histamine
murine histamine H4 receptor;
ment
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ll.fuxe@ki.se (K. Fuxe),
rights reserved.the well-established role of histamine in promoting wakefulness and
cognitive alertness, H3 receptor antagonists have shown clinical
promise for the treatment of disorders of excessive daytime sleepiness,
such as narcolepsy [7]; however, compounds with H3 receptor activity
are also being investigated for a variety of other conditions, including
dementia, schizophrenia, epilepsy, obesity, and neuropathic pain [1,2].
The H3 receptor mRNA transcript undergoes extensive splicing,
giving rise to a variety of species-speciﬁc isoforms [8]. Interestingly, it
has recently been found that shortened isoforms of the H3 receptor
serve the role of histamine autoreceptors in rat brain [9]. The 445-
residue human histamine H3445 receptor (hH3445) was the ﬁrst isoform
to be cloned, and is usually referred to as the full-length, or long, isoform
[8]. The human histamine H3365 receptor (hH3365) is the second most
abundantly expressed isoform after hH3445, but has higher afﬁnity for
histamine and higher constitutive activity [10,11]. This splice variant
lacks 80 amino acids in the C-terminal third intracellular loop as
compared to hH3445 and belongs to the short isoforms. Notably, this
80-residue deletion encompasses an aspartate residue at the cytoplasmic
end of transmembrane segment (TM)VI. A negatively charged residue in
this position (position number 6.30 in the numbering scheme of
Ballesteros and Weinstein [12]) is conserved among most amine
GPCRs, and has been proposed to play an important role in their activa-
tion mechanism [13,14].
The human histamine H4 (hH4) receptor shares ~35% protein
sequence identity with the hH3445 receptor. Of the four histamine recep-
tors, the histamine H4 receptor is the least conserved amongmammals,
at the level of amino acid sequence. In particular, the third intracellular
loop shows the largest variability between species [15]. Similarly to
3082 K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089hH3365, both the human andmurine (mH4) H4 receptors lack a negatively
charged residue in position 6.30; instead, an alanine or glycine residue,
respectively, occupies this position. The H4 receptor has been described
to be expressed predominantly in cells of the haematopoietic system,
where it regulates activation, secretion of immune mediators, and
migration of several cell types [16]. A recent study presented immuno-
histochemical and functional electrophysiology data suggesting the
postsynaptic expression of the H4 receptor on central neurons [17].
However, the speciﬁcity of available H4 receptor antibodies is presently
a matter of considerable debate [18–20], and the purported location of
the H4 receptor in the central nervous system thus remains a controver-
sial issue. H4 receptor ligands are being investigated for therapeutic
utility in several inﬂammatory and autoimmune disorders, as well
as for analgesic activity [1,2]. An alignment of the primary sequences
of the hH3445, hH3365, hH4, and mH4 receptors is shown in Fig. 1.
In recent years, evidence has indicated that ligand binding to GPCRs
can be regulated by the transmembrane potential [21], a property
which has been implicated in autoreceptor function [22]. Decreased
agonist potency and binding afﬁnity at Gi/o-coupled muscarinic M2,
glutamate mGluR3, and dopamine D2 receptors at depolarized mem-
brane potentials was demonstrated, by using G-protein coupled inward
rectiﬁer potassium (GIRK) channel opening as readout of receptor
activity in electrophysiological assays, and by radiolabeled agonist
binding experiments [23–25]. Furthermore, voltage-induced movement
of “gating charge”, and of ﬂuorescently labelled residues in the ligand
binding pocket, were recorded in the case of the M2 receptor [23].
Although the putative GPCR voltage sensor remains unidentiﬁed,
the third intracellular loop has been shown to play a crucial role in
the mechanism coupling this sensor to the ligand binding site. The
G protein-interacting properties of the loop, with particular emphasis
on a conserved basicmotif in its N-terminal portion, have been proposed
to be particularly important in this regard [23] (see Fig. 1).
GIRK channels are opened by the binding of Gβγ subunits released
from Gi/o proteins and hence the time course of GIRK activity closely
follows the activity of coexpressed Gi/o-coupled receptors [26,27].
Importantly, GIRK activation by Gβγ is not in itself a voltage sensitive
process [24]. Besides its utility in the investigation of GPCR voltage
sensitivity, the GIRK activation assay enables comparison of signaling
kinetics between different receptors being activated by the same agonist,
or between different agonists acting via the same receptor [26–28].
Notably, the rate of receptor deactivation upon agonist removal,
reﬂecting agonist unbinding from the receptor, can be studied. The rate
of agonist unbinding is likely to have consequences for autoreceptor
function by affecting the time course of presynaptic inhibition [26]. We
previously demonstrated both hH3445 and hH4 receptors to activate
GIRK channels when coexpressed in Xenopus oocytes [28,29]. In the
present study, we used the GIRK assay to examine deactivation kinetics
and the impact of transmembrane voltage on hH3445, hH3365, hH4, and
mH4 receptors when stimulated by histamine. Furthermore, to investi-
gate the role of the 6.30 residue in determining receptor characteristics,
we used site-directed mutagenesis to exchange the identity of this
residue between the hH3445 and hH4 receptors.
2. Materials and methods
2.1. Molecular biology
Human GIRK1 (Kir3.1) and GIRK4 (Kir3.4) cDNA (provided by
Dr. Terence Hebert, University of Montreal, Canada), cDNA encoding
the hH4 receptor (purchased from the UMR cDNA resource center,
Rolla,MO), and the hH3365 andmH4 receptors (synthesized byGenScript
USA Inc., Piscataway, NJ) were all in pCDNA3 (Invitrogen). cDNA en-
coding the full-length hH3445 receptor in pCI-neo (Promega) was
obtained from the laboratory of Dr. Rafael Franco, University of Barcelona.
Plasmids were linearized with the appropriate restriction enzymes and
transcribed in vitro using the T7 mMessage mMachine kit (Ambion,Austin, TX). Site-directed mutagenesis to generate the hH3445 D353A and
hH4 A298D mutants was performed using the QuickChange Lightning
kit (Agilent, Santa Clara, CA). The mutated constructs were veriﬁed by
sequencing of the entire inserts.
2.2. Oocyte isolation and injection
Oocytes were surgically removed from female African clawed toads,
Xenopus laevis, as previously described [29]. Ethical approval for the
procedure had been granted by the Swedish National Board for Laborato-
ry Animals. The oocytes were incubated overnight at 12 °C in modiﬁed
Barth's solution, containing (in mM): 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.015
HEPES, 0.33 Ca(NO3)2, 0.41 CaCl2, 0.82 MgSO4, pH 7.6 with NaOH,
supplemented with 10 μg/ml pyruvate and 10 μg/ml penicillin-
streptomycin. The following day, oocytes were injected with cRNA
(50 nl/cell) using a Nanoject injector (Drummond Scientiﬁc), and incu-
bated for another 4 to 7 days prior to the electrophysiology experiments.
The amounts of cRNA injected were 1 ng/oocyte for each of the GIRK
subunits, and when used in the respective experiments, 6 ng/oocyte
for either one of the hH3445 and hH4 receptors, 18 ng/oocyte for the
hH3365 receptor, 2 ng/oocyte for the mH4 receptor, 12 ng/oocyte for
the hH3445 D353A mutant, and 1 ng/oocyte for the hH4 A298D mutant.
The amounts of receptor cRNA were adjusted to give optimal GIRK
response amplitudes.
2.3. Electrophysiology
The electrophysiological experiments were performed using the
two-electrode voltage-clamp technique as described earlier [29].
Experiments were carried out at room temperature (20–22 °C). For re-
cording of GIRK currents, a high-potassium solution (in mM; 64 NaCl,
25 KCl, 0.8 MgCl2, 0.4 CaCl2, 15 HEPES, 1 ascorbic acid, adjusted to pH
7.4) was used, giving a K+ reversal potential of about −40 mV. Two
types of pulse protocolswere used to evokeGIRK currents fromaholding
potential of−40 mV; 20 increasingly negative 800 ms-pulses from+50
to−120 mV were used to visualize the voltage-dependence of channel
opening, whereas single −80 and +40 mV pulses of longer duration
were applied, in random order, to study current responses to histamine
receptor ligand application at the respective potentials.
2.4. Agonist stimulation
Histamine base (≥97% purity) and VUF8430 dihydrobromide (≥98%
purity) were obtained from Sigma–Aldrich, and RAMH dihydrobromide
(>99% purity) was purchased from Tocris Bioscience. Agonist ligands
were dissolved in water and diluted in recording solution to the desired
concentrations. During the electrophysiology experiments, agonists
were added by superfusion at ~1.5 ml/min using a controlled-ﬂow
perfusion system (SmartSquirt; AutoMate Scientiﬁc, Berkeley, CA).
Three to six increasing concentrations of agonist were applied consecu-
tively at the same intervals at both potentials, ending with a response-
saturating concentration. For each oocyte and each holding voltage, the
evoked current response for each concentration tested was normalized
to the maximal agonist response obtained in the same oocyte. The
evoked current response was determined by subtracting the basal
(agonist-independent) current from the peak current amplitude
following histamine application.
2.5. Data analysis
Variable slope sigmoidal concentration–response curveswereﬁtted to
the concentration–response data usingGraphPadPrism(PrismSoftware).
The following equation was used for ﬁtting: Y=top/(1+10^((log
EC50−X)×n)) where Y is the response as a fraction of 1, top is the
maximal response, X is the logarithm of agonist concentration and
n is the Hill slope. Analyses of variance (F-test) were performed on
Fig. 1. Alignments of amino acid sequences of the hH3445, hH3365, hH4, and mH4 receptors, as indicated, made with the ClustalW online tool. Basic residues are shown in bold type,
whereas italics denote acidic residues. * indicates completely conserved residues, :indicates highly conserved, and .moderately conserved residues. Black bars indicate the locations of
the putative transmembrane segments (TMs). The basic motif in the third intracellular loop proposed to be important for coupling of the receptor to G protein, and for coupling the GPCR
voltage sensor to the agonist binding site, is highlighted in light grey. Residue 6.30 (see main text) is indicated in dark grey. The sequences shown are identical to the corresponding
GenBank ID; NP_009163.2 (hH3445), AAL71912.1 (hH3365), NP_067637.2 (hH4), and NP_694727.1 (mH4).
3083K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089the ﬁtted curves, testing the differences between the estimated log
EC50s at the two transmembrane voltages. Pb0.05 was chosen as the
signiﬁcance limit. GIRK current deactivation kinetics were quantiﬁed
by ﬁtting a monoexponential decay function; y=y0+A×e−(t−t0)/τ,
to data, to estimate the time constant of response decay upon agonistwashout. y is used to describe current amplitude, t is time, A is the
current amplitude at the start of the ﬁt, and τ is the time constant
of current decay. Paired Student's t-test was used to assess statistical
signiﬁcance between GIRK deactivation kinetics recorded at −80
and 0 mV. In these experiments, data was always acquired from
3084 K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089both potentials in each cell. Unpaired Student's t-test was used to
compare deactivation kinetics between GIRK responses elicited via
different receptors. In both cases, Pb0.05 was chosen as the signiﬁ-
cance limit.
3. Results
3.1. Histamine potency in GIRK activation by histamine H3 and H4 receptors
at−80 mV and 0 mV
The procedures used for oocyte recording were as described [29].
In short, oocytes were superfused with a high potassium (25 mM)
solution and basal currents were evoked either by a hyperpolarizing
step to −80 mV or by a depolarizing step to 0 mV. The hyper- orFig. 2. Representative traces showing hH3445 (A) and hH4 (B) and hH3365 (C) receptor-mediated G
as indicated. Both traces shown for each receptor subtype were recorded in the same cell. The e
EC50; the lower agonist potency at 0 mV vs.−80 mV is apparent, e.g., when comparing the relat
scale in (C), as compared to (A) and (B).depolarizing potential was maintained throughout application and
washout of histamine. Concentration–response curves were constructed
for the increase in GIRK current amplitudes elicited via histamine recep-
tor activationwhen the oocytemembranewas voltage-clamped at 0 mV
or at−80 mVas described previously [25] (see Fig. 2). Histamine did not
elicit any current responseswhenapplied at 10 μMtooocytes expressing
GIRK channel subunitswithout histamine receptors, norwhen applied to
oocytes expressing histamine receptors alone, at either potential (data
not shown), thus supporting the notion that the measured responses
were indeed reﬂective of the activation of GIRK channels by the his-
tamine H3 and H4 receptors.
We found histamine potency to be signiﬁcantly lower at 0 mV
vs. −80 mV at both the hH3445 and hH3365 isoforms, as well as at the
hH4 and mH4 receptors. The voltage-induced potency shift was largestIRK current responses to increasing concentrations of histamine at 0 mV and at−80 mV,
ffects of voltage on agonist potency are themost pronounced at concentrations around the
ive responses to 100 nMhistamine in (a), at the twopotentials. Note the difference in time
3085K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089at the hH3445 receptor with about a 2.8-fold difference between voltages,
whereas the shift was 2-fold at the hH3365 receptor, and only 1.7-fold at
the hH4 and mH4 receptors (see Fig. 2, Fig. 3, and Table 1).3.2. GIRK deactivation rates at −80 mV and 0 mV
Agonist off-rates at Gi/o-coupled receptors can be compared via the
GIRK current response deactivation time course upon ligand washout
[26,27]. We have previously shown that the deactivation rate upon
washout of the agonist (R)-α-methylhistamine (RAMH), which has
low afﬁnity for the hH4 receptor, is signiﬁcantly more rapid than that
of the high-afﬁnity hH4 partial agonist clobenpropit [28]. Additionally,
the alterations in receptor afﬁnity for agonist by transmembrane voltage
have been shown to be reﬂected in changes in the ligand off-rates at the
mGluR3 [24]. To investigate whether the voltage sensitivities of H3 and
H4-mediated GIRK response concentration–response relationships
were due to a similar mechanism, we compared the washout time
courses of the H3 and H4-mediated GIRK responses to histamine at
0 mV and at −80 mV (Fig. 4, Table 1). In agreement with the above
ﬁndings, the time constant of GIRK current decay following histamine
washout was signiﬁcantly faster at the depolarized potential when the
response was evoked via the hH3445 and hH3365 receptors. However,
when the hH4 receptor was stimulating GIRK channels, there was noFig. 3. Concentration–response relationships for histamine-induced GIRK activation by wt a
0 mV as indicated. Curves were ﬁtted to data as described in Materials and methods, subsesigniﬁcant difference between the current decay time constants at the
twopotentials. A strikingﬁnding in these experimentswas that the cur-
rent decay time course was about ﬁve to six-fold slower, at both poten-
tials, in experiments with the hH3365 receptor compared to the hH3445
receptor.3.3. Inﬂuence of residue 6.30 over receptor voltage sensitivity and GIRK
deactivation rates
Since both the hH3365 and hH4 receptors lack a negatively charged
residue in position 6.30, as opposed tomost amine GPCRs including the
hH3445 receptor, we decided to test the inﬂuence of this residue over
receptor voltage sensitivity and GIRK deactivation time course.We thus
investigated two receptor mutants; hH4 A298D and hH3445 D353A.
At the hH4 A298D mutant, there was no statistical difference in
histamine potency between 0 mV and−80 mV, whereas at the hH3445
D353A mutant, the voltage-induced shift was signiﬁcant, and very
similar to that observed with the wt receptor (Fig. 3, Table 1). Further-
more, compared to thewt receptor, thewashout time coursewas signif-
icantly slower in experiments using the hH3445 D353A mutant, at 0 mV
but not at−80 mV (Fig. 4, Table 1). The washout time constants were
not signiﬁcantly different, at either potential, between the hH4 A298D
mutant and wt hH4 receptors.nd mutant hH3445 and hH4 receptors, and wt hH3365 and mH4 receptors, at−80 mV and
ction 2.5. See Table 1 for agonist potency values and statistical analyses.
Table 1
Effects of membrane voltage on histamine potencies in activating GIRK, and GIRK deactivation time constants upon histamine washout, in oocytes expressingwt and mutant histamine
receptors.
Receptor n pEC50±S.E.M. (EC50, nM) EC50 ratio 0 mV/−80 mV Tau (s)±S.E.M. Tau ratio −80 mV/0 mV
0 mV −80 mV 0 mV −80 mV
hH3365 4–7 7.92±0.07 (12.0) 8.21±0.05 (6.15) 1.95 *** 141±15 272±20 1.94 **
hH3445 3–10 6.75±0.03 (177) 7.20±0.03 (63.8) 2.76 *** 26.4±1.3 42.3±5.9 1.60 *
hH3445 D353A 4 7.40±0.08 (39.6) 7.86±0.04 (14.0) 2.83 *** 38.6±2.8 ††† 58.4±3.4 1.51 ***
hH4 5–9 7.55±0.02 (28.4) 7.77±0.02 (16.9) 1.68 *** 40.4±5.7 44.9±3.6 1.11
hH4 A298D 3–6 6.92±0.11 (121) 6.97±0.04 (108) 1.12 41.2±5.4 35.6±2.6 0.865
mH4 4 6.45±0.06 (352) 6.68±0.04 (211) 1.66 ** 24.7±3.0 31.2±1.6 1.26 *
Asterisks denote statistically signiﬁcant differences in pEC50s between membrane potentials; **, Pb0.01; ***, Pb0.001 (F-test), and differences in deactivation time constants
between membrane potentials; *, Pb0.05; **, Pb0.01; ***, Pb0.001 (Student's paired t-test). ††† Signiﬁcantly different from deactivation time constant at the wt hH3445 receptor
at 0 mV (Pb0.001, Student's unpaired t-test).
3086 K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–30893.4. Effects of voltage on synthetic H3 and H4 receptor agonists
Wehavepreviously presented evidence that the potencies of different
agonists at the dopamine D2S receptor are differentially affected by the
receptor's voltage sensitivity, likely depending on the speciﬁc agonist–
receptor interactions involved [30]. To investigate whether receptor
voltage sensitivity might have distinct effects on different histamine
receptor agonists, we investigated the effects of voltage on the po-
tencies of the H3-selective agonist, RAMH [31], and the H4-selective,
nonimidazole agonist, VUF8430 [32], acting via the hH3445 and hH4
receptors (see Fig. 5).
At the hH3445 receptor, RAMH displayed a signiﬁcant, 2.4-fold reduc-
tion in potency at 0 mV as compared to−80 mV, whereas at the hH4
receptor, there was no signiﬁcant difference in RAMH potency between
these two potentials. In agreement, the GIRK deactivation rate upon
RAMH washout was signiﬁcantly faster at 0 mV than at−80 mV when
currents were elicited via the hH3445 receptor, while the deactivation
rate was similar at 0 mV and at−80 mV in experiments with the hH4
receptor (Fig. 5, Table 2).
VUF8430 was found to directly block the GIRK channel at concen-
trations exceeding 10 μM (data not shown), and it was therefore not
possible to obtain a clear plateau for the GIRK response elicited by this
agonist via the hH4 receptor. Therefore, in every cell and at each mem-
brane potential, we normalized the responses to each concentration ofFig. 4. GIRK current deactivation time constants upon histaminewashout recorded at 0 mV
and at−80 mV, in oocytes coexpressing GIRK channels with wt andmutant histamine re-
ceptors, as indicated. Note the offset Y-axis, to accommodate the time constants for the
hH3365 receptor. Asterisks denote statistically signiﬁcant differences in deactivation time
constants between membrane potentials; *, Pb0.05; **, Pb0.01; ***, Pb0.001 (Student's
paired t-test). ††† Signiﬁcantly different from deactivation time constant at the wt hH3445
receptor at 0 mV (Pb0.001, Student's unpaired t-test).VUF8430 to the maximal response to histamine (10 μM) obtained at
the respective membrane potential in that cell. VUF8430 displayed a
marked and signiﬁcant potency reduction of about 3.1-fold at 0 mV
compared to−80 mV, when acting via the hH4 receptor. Corresponding-
ly, the rate of GIRK deactivationwas signiﬁcantly faster at the depolarized
potential than at the hyperpolarized potential (Fig. 5, Table 2).
As has been previously reported [32], VUF8430 is considerably less
potent at the hH3445 receptor than at the hH4 receptor, and because of
its GIRK-blocking properties, it was not possible to study the actions
of this compound at hH3445 receptor using the GIRK activation assay.4. Discussion
As recently reviewed by Parnas and Parnas [22], there are strong indi-
cations that presynaptic, Gi/o-coupled muscarinic M2 and glutamatergic
mGluR3 receptors interact intimately with the vesicle release machinery
to regulate transmitter release, inhibiting vesicle fusion in an agonist-
dependent manner. Furthermore, experimental evidence suggests that
voltage sensitive agonist potency at these autoreceptors plays a crucial
role in regulating the kinetics of neurotransmitter release [22].
Notably, the voltage sensitivity of the hH3445 receptor described here
is similar to that of the muscarinic M2 receptor (c.f. results in Sahlholm,
[33]). The hH3365 isoform and the hH4 receptor have been described to
share certain features with the dopamine D3 receptor, such as G
protein-insensitive high-afﬁnity binding to agonists [10,34,35]. We
reported earlier that dopamine potency at the dopamine D3 receptor
was not signiﬁcantly affected by depolarization from −80 to 0 mV
[25]. However, a signiﬁcant rightward potency shift upon depolariza-
tion was observed with the hH3365 isoform and with hH4, although the
extents of these shifts were smaller than observedwith hH3445, especially
for hH4. Notably, histamine H3 receptors are known to function as
auto- and heteroreceptors, regulating release from several types of
nerve terminals [4,8,9]. Conversely, this function is less likely for the
histamineH4 receptor, as it is predominantly expressed in hematopoietic
cells [16]. The weaker voltage sensitivity of the histamine hH4 receptor,
as compared to the hH3 receptors, might relate to such differences in
functional roles.
Since the third intracellular loop has been shown to be important
for GPCR voltage sensitivity [23], we evaluated mH4 in our GIRK assay
to assess the putative functional impact of the sequence divergence
between this receptor and hH4. Notably, this sequence divergence is
particularly pronounced in the region of the third intracellular loop.
However, the extent of the voltage-induced potency shift, as well as
the rate of deactivation, were similar to that observed with the hH4
receptor, with the exception that a small but signiﬁcant difference in
deactivation time constants was observed between the two voltages
at the mH4 receptor. This suggests that the species differences in third
intracellular loop sequences do not have a major impact on voltage
sensitivity in this case.
Fig. 5. Effects of histamine receptor voltage sensitivity on synthetic agonist potency. (A) Chemical structures of the three agonists used in the present study. (B) Concentration–response
relationships for GIRK activation bywt hH3445 and hH4 receptors at−80 mV and 0 mV as indicated. Curves were ﬁtted to data as described inMaterials and methods, subsection 2.5. See
Table 2 for agonist potency values and statistical analyses. (C) GIRK current deactivation time constants uponwashout of synthetic agonists, recorded at 0 mV and at−80 mV in oocytes
coexpressing GIRK channels withwt hH3445 and hH4 histamine receptors, as indicated. Asterisks denote statistically signiﬁcant differences in deactivation time constants between
membrane potentials; *, Pb0.05 (Student's paired t-test).
3087K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089The negatively charged residue in position 6.30, which is con-
served in many amine GPCRs, has been implicated in maintaining
the receptor in an inactive conformation by forming part of the
“ionic lock” [13,14]. Indeed, charge-neutralizing mutations of this
residue have been shown to increase constitutive activity and agonist
afﬁnity in some GPCRs [13,14]. Since the voltage sensor in amine
GPCRs yet remains to be identiﬁed [23], we were interested in whether
this conserved residue could play a role in voltage sensing. However,Table 2
Effects of membrane voltage on synthetic agonist potencies in activating GIRK, and GIRK d
hH3445 and hH4 receptors.
Agonist/receptor n pEC50±S.E.M. (EC50, nM) EC50 r
0 mV −80 mV
RAMH/hH3445 3–8 7.57±0.07 (26.9) 7.96±0.06 (11.0) 2.44 *
RAMH/hH4 3–6 6.41±0.08 (387) 6.48±0.06 (331) 1.17
VUF8430/hH4 7 6.04±0.16 (913) 6.54±0.14 (291) 3.13 *
Asterisks denote statistically signiﬁcant differences in pEC50s between membrane potent
between membrane potentials; *, Pb0.05 (Student's paired t-test).altering the charge in position 6.30 by D353A mutation in the
hH3445 receptor and by A298D mutation in the H4 receptor did not
“switch” voltage sensitivities between the receptors, as might have
been expected if this residue was a major determinant of GPCR volt-
age sensitivity. Similarly, the corresponding mutation, E339A, of the
dopamine D2S receptor does not diminish the voltage sensitivity of
dopamine potency at this receptor (Sahlholm et al., unpublished
observations).eactivation time constants upon agonist washout, in oocytes expressing wt histamine
atio 0 mV/−80 mV Tau (s)±S.E.M. Tau ratio −80 mV/0 mV
0 mV −80 mV
** 34.1±2.0 47.0±2.6 1.38 *
20.6±1.5 23.2±1.1 1.13
20.9±1.4 30.0±2.8 1.44 *
ials; *, Pb0.05; ***, Pb0.001 (F-test), and differences in deactivation time constants
3088 K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089We have previously reported that the potencies of various agonists
at the dopamineD2S receptor are differentially affected by the receptor's
voltage sensitivity [30]. Agonist-speciﬁc voltage sensitivity represents a
new form of functional selectivity, which could potentially be exploited,
e.g.,when investigating the physiological roles of GPCRvoltage sensitivity
in native tissue. In the present investigation, we found evidence for
agonist-speciﬁc effects of histamine receptor voltage sensitivity; the syn-
thetic nonimidazole H4 agonist VUF8430 displayed a depolarization-
induced potency reduction at the hH4 receptor which was markedly
larger than that observed for histamine and RAMHat the same receptor.
Somewhat varying ﬁgures have been reported for the extracel-
lular concentration of histamine in the brain as measured by in vivo
microdialysis; concentrations of about 5 nM [36] to 50 nM [37,38] have
been reported for the rat striatum. It is interesting to note that these
ﬁgures fall within the range of concentrations where pronounced
modulation by voltage was observed in the present study. Although
the impact of voltage on the level of a speciﬁc effector system, at a
given concentration of agonist, would be dependent on the receptor
reserve of the tissue [39], H3 and H4 receptor occupancy would likely
be affected by voltage, since these receptors would not be saturated at
the extracellular concentrations of histamine found in vivo, as implied
by the present results and as demonstrated in ligand binding experiments
[10,40]. It is thus reasonable to speculate that the voltage-sensitivities of
the histamine receptors described here could have an impact on their
activity under physiological circumstances.
The rate of GIRK response decay upon agonist washout has been
strongly linked to the relative stability of the ternary complex of agonist,
receptor, and G protein, and consequently reﬂects the rate of agonist
unbinding from the ternary complex [27]. The present observations
thus suggest that the reported higher afﬁnity of histamine for the
hH3365 vs. the hH3445 isoform [10] likely reﬂects a slower off-rate of the
agonist at the hH3365 receptor, and a slower breakdown of the ternary
complex as a whole. A similarly slow GIRK response deactivation rate
has been described for the dopamine D3 receptor [41].
The hH3445 D353A mutation slowed the deactivation time course
only about 1.5-fold relative to the wt hH3445 receptor, which should be
compared to the over ﬁve-fold slower kinetics of the hH3365 receptor.
Deactivation kinetics at the hH4 A298D mutant were not signiﬁcantly
different from the wt hH4 receptor. Taken together, the present results
suggest that this residue does not play any major role in determining
the differences in voltage sensitivity or washout characteristics between
hH3445, hH3365, and hH4 receptors. Similarly, a recent study [42] demon-
strated that A298E mutation of the H4 receptor had no signiﬁcant effects
on the high constitutive activity of this receptor.
The slower response decay rate upon agonist washout at hH3365 vs.
hH3445might have functional consequences in vivo. Indeed, the hH3365 and
hH3445 isoforms showdistinct patterns ofmRNA expression in the human
brain, with the hH3365 isoform being predominant in several areas [10].
Whereas any putative differences in the subcellular distributions of the
H3 receptor isoforms have yet to be described, the pharmacology of the
short H3 receptor isoforms clearly differs from that of the long, H3445
isoform, as recently demonstrated by Gbahou et al. [9]. These authors
took advantage of the pharmacological differences to demonstrate the
speciﬁc involvement of the short H3 receptor isoforms as histaminergic
autoreceptors in rat. Gbahou et al. [9] speculated that the H3445 isoform,
in contrast, functions as a heteroreceptor and/or postsynaptic receptor.
In this context, is interesting to note that the differential inﬂuence of
adrenergic α2A and α2C autoreceptors over noradrenaline release at
different rates of presynaptic stimulation [43] was found to correlate
with their differential afﬁnities and deactivation kinetics upon agonist
washout [26]. The α2C receptor displays higher afﬁnity and slower re-
sponse termination rate, and speciﬁcally inhibits noradrenaline trans-
mission at low release frequencies, whereas the lower-afﬁnity, faster
deactivating α2A receptor only comes into play at higher release fre-
quencies,when the concentration of noradrenaline builds up at the syn-
apse [26,43]. It is thus plausible that similar differences in physiologicalroles might apply to the hH3445 and hH3365 isoforms. It should be noted
that the hH3365 transcript is more abundant than the hH3445 transcript
in the hypothalamus [10], where the histaminergic tuberomammillary
nucleus is located giving rise to all histamine pathways projecting to var-
ious parts of the brain. Thus, it is possible that the hH3365 isoform could
serve an autoreceptor role on tuberomammillary histamine neu-
rons, providing long-lasting negative feedback on their ﬁring rates
already at low histamine concentrations. On the other hand, the
hH3445 might function as a heteroreceptor, intermittently inhibiting
the release of other neurotransmitters at higher concentrations of
histamine.
5. Conclusion
The present study identiﬁed novel functional properties in terms of
voltage sensitivities and deactivation rates, which differed between the
histaminehH3445, hH3365, andH4 receptors. All receptors displayed varying
degrees of voltage sensitive histamine potency, which was the most
pronounced at the hH3445 receptor, and the weakest at the hH4 and
mH4 receptors. Furthermore, the hH3365 receptor was found to display
a strikingly slow rate of response decay upon agonist washout, likely
reﬂecting a slower rate of agonist unbinding from this receptor. The
identity of residue 6.30 was found not to inﬂuence voltage sensitivity,
and to have aminor effect on deactivation kinetics upon agonistwashout.
Finally, we obtained evidence for agonist-speciﬁc voltage sensitivity at
the hH4 receptor. The different properties of histamine hH3445, hH3365,
and H4 receptors described here may be relevant to their respective
physiological functions.
Role of the funding source
The funding sources, listed under “Acknowledgements”, had no role
in study design, in the collection, analysis, and interpretation of data, in
manuscript writing, or in the decision to submit the manuscript.
Acknowledgements
This study was supported by grants from the Swedish Research
Council (Grant No 15083 and 04X-715), the Swedish Society ofMedicine,
KI funds, the Swedish Society for Medical Research, and Magn. Bergvalls
Stiftelse.
References
[1] E. Tiligada, E. Zampeli, K. Sander, H. Stark, Histamine H3 and H4 receptors as
novel drug targets, Expert Opin. Investig. Drugs 18 (2009) 1519–1531.
[2] R. Leurs, H.F. Vischer, M. Wijtmans, I.J. de Esch, En route to new blockbuster
anti-histamines: surveying the offspring of the expanding histamine receptor
family, Trends Pharmacol. Sci. 32 (2011) 250–257.
[3] C. Pillot, A. Heron, V. Cochois, J. Tardivel-Lacombe, X. Ligneau, J.C. Schwartz, J.M.
Arrang, A detailed mapping of the histamine H(3) receptor and its gene transcripts
in rat brain, Neuroscience 114 (2002) 173–193.
[4] J.M. Arrang, M. Garbarg, J.C. Schwartz, Auto-inhibition of brain histamine release
mediated by a novel class (H3) of histamine receptor, Nature 302 (1983) 832–837.
[5] E. Sánchez-Lemus, J.A. Arias-Montaño, Histamine H3 receptor activation inhibits
dopamine D1 receptor-induced cAMP accumulation in rat striatal slices, Neurosci.
Lett. 364 (2004) 179–184.
[6] C. Ferrada, S. Ferré, V. Casadó, A. Cortés, Z. Justinova, C. Barnes, E.I. Canela, S.R.
Goldberg, R. Leurs, C. Lluis, R. Franco, Interactions between histamine H3 and dopa-
mine D2 receptors and the implications for striatal function, Neuropharmacology 55
(2008) 190–197.
[7] J.C. Schwartz, The histamine H3 receptor: from discovery to clinical trials with
pitolisant, Br. J. Pharmacol. 163 (2011) 713–721.
[8] R. Leurs, R.A. Bakker, H. Timmerman, I.J. de Esch, The histamine H3 receptor: from
gene cloning to H3 receptor drugs, Nat. Rev. Drug Discov. 4 (2005) 107–120.
[9] F. Gbahou, A. Rouleau, J.M. Arrang, The histamine autoreceptor is a short isoform
of the H(3) receptor, Br. J. Pharmacol. 166 (2012) 1860–1871.
[10] G. Bongers, K.M. Krueger, T.R. Miller, J.L. Baranowski, B.R. Estvander, D.G. Witte, M.I.
Strakhova, P. van Meer, R.A. Bakker, M.D. Cowart, A.A. Hancock, T.A. Esbenshade, R.
Leurs, An 80-amino acid deletion in the third intracellular loop of a naturally occurring
human histamine H3 isoform confers pharmacological differences and constitutive
activity, J. Pharmacol. Exp. Ther. 323 (2007) 888–898.
3089K. Sahlholm et al. / Biochimica et Biophysica Acta 1818 (2012) 3081–3089[11] T.A. Esbenshade, M.I. Strakhova, T.L. Carr, R. Sharma, D.G. Witte, B.B. Yao, T.R.
Miller, A.A. Hancock, Differential CNS expression and functional activity of multiple
human H(3) receptor isoforms, Inﬂamm. Res. 55 (2006) S38–S39.
[12] J.A. Ballesteros, H. Weinstein, Integrated methods for the construction of three
dimensional models and computational probing of structure function relations
in G protein-coupled receptors, Methods Neurosci. 25 (1995) 366–428.
[13] J.A. Ballesteros, A.D. Jensen, G. Liapakis, S.G. Rasmussen, L. Shi, U. Gether, J.A.
Javitch, Activation of the beta 2-adrenergic receptor involves disruption of an
ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6,
J. Biol. Chem. 276 (2001) 29171–29177.
[14] R. Moukhametzianov, T.Warne, P.C. Edwards, M.J. Serrano-Vega, A.G. Leslie, C.G. Tate,
G.F. Schertler, Two distinct conformations of helix 6 observed in antagonist-bound
structures of a beta1-adrenergic receptor, Proc. Natl. Acad. Sci. U. S. A. 108 (2011)
8228–8232.
[15] C. Liu, S.J. Wilson, C. Kuei, T.W. Lovenberg, Comparison of human, mouse, rat, and
guinea pig histamine H4 receptors reveals substantial pharmacological species
variation, J. Pharmacol. Exp. Ther. 299 (2001) 121–130.
[16] R.L. Thurmond, E.W.Gelfand, P.J. Dunford, The role of histamineH1 andH4 receptors
in allergic inﬂammation: the search for new antihistamines, Nat. Rev. Drug Discov. 7
(2008) 41–53.
[17] W.M. Connelly, F.C. Shenton, N. Lethbridge, R. Leurs, H.J. Waldvogel, R.L. Faull, G.
Lees, P.L. Chazot, The histamine H4 receptor is functionally expressed on neurons
in the mammalian CNS, Br. J. Pharmacol. 157 (2009) 55–63.
[18] S. Beermann, R. Seifert, D. Neumann, Commercially available antibodies against
human and murine histamine H₄-receptor lack speciﬁcity, Naunyn Schmiedebergs
Arch. Pharmacol. 385 (2012) 125–135.
[19] R. Gutzmer, T. Werfel, W. Bäumer, M. Kietzmann, P.L. Chazot, R. Leurs, Well char-
acterized antihistamine 4 receptor antibodies contribute to current knowledge of
the expression and biology of the human and murine histamine 4 receptor,
Naunyn Schmiedebergs Arch. Pharmacol. 385 (2012) 853–854.
[20] D. Neumann, S. Beermann, S.Mägel, D. Jonigk, D.Weber-Steffens, D.Männel, R. Seifert,
Problems associated with the use of commercial and non-commercial antibodies
against the histamine H(4) receptor, Naunyn Schmiedebergs Arch. Pharmacol.
385 (2012) 855–860.
[21] M.P. Mahaut-Smith, J. Martinez-Pinna, I.S. Gurung, A role for membrane potential
in regulating GPCRs? Trends Pharmacol. Sci. 29 (2008) 421–429.
[22] I. Parnas, H. Parnas, Control of neurotransmitter release: From Ca2+ to voltage
dependent G-protein coupled receptors, Pﬂugers Arch. 460 (2010) 975–990.
[23] N. Dekel, M.F. Priest, H. Parnas, I. Parnas, F. Bezanilla, Depolarization induces a
conformational change in the binding site region of the M2 muscarinic receptor,
Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 285–290.
[24] L. Ohana, O. Barchad, I. Parnas, H. Parnas, The metabotropic glutamate G-protein-
coupled receptors mGluR3 and mGluR1a are voltage-sensitive, J. Biol. Chem. 281
(2006) 24204–24215.
[25] K. Sahlholm, D. Marcellino, J. Nilsson, K. Fuxe, P. Arhem, Differential voltage-
sensitivity of D2-like dopamine receptors, Biochem. Biophys. Res. Commun. 374
(2008) 496–501.
[26] M. Bünemann, M.M. Bücheler, M. Philipp, M.J. Lohse, L. Hein, Activation and deactiva-
tion kinetics of alpha 2A- and alpha 2C-adrenergic receptor-activated G protein-
activated inwardly rectifying K+ channel currents, J. Biol. Chem. 276 (2001)
47512–47517.[27] A. Benians,M. Nobles, A. Tinker, Agonist unbinding from receptor dictates the nature
of deactivation kinetics of G protein-gated K+ channels, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 6239–6244.
[28] K. Sahlholm, J. Nilsson, D. Marcellino, K. Fuxe, P. Arhem, Electrophysiology-based
analysis of human histamine H(4) receptor pharmacology using GIRK channel
coupling in Xenopus oocytes, Eur. J. Pharmacol. 591 (2008) 52–58.
[29] K. Sahlholm, J. Nilsson, D. Marcellino, K. Fuxe, P. Arhem, The human histamine H3
receptor couples to GIRK channels in Xenopus oocytes, Eur. J. Pharmacol. 567
(2007) 206–210.
[30] K. Sahlholm, O. Barchad-Avitzur, D. Marcellino, M. Gómez-Soler, K. Fuxe, F.
Ciruela, P. Arhem, Agonist-speciﬁc voltage sensitivity at the dopamine D2S receptor–
molecular determinants and relevance to therapeutic ligands, Neuropharmacology
61 (2011) 937–949.
[31] J.M. Arrang, M. Garbarg, J.C. Lancelot, J.M. Lecomte, H. Pollard, M. Robba, W.
Schunack, J.C. Schwartz, Highly potent and selective ligands for histamine
H3-receptors, Nature 327 (1987) 117–123.
[32] H.D. Lim, R.A. Smits, R.A. Bakker, C.M. van Dam, I.J. de Esch, R. Leurs, Discovery of
S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine
H4 receptor agonist, J. Med. Chem. 49 (2006) 6650–6651.
[33] K. Sahlholm, The role of RGS protein in agonist-dependent relaxation of GIRK currents
in Xenopus oocytes, Biochem. Biophys. Res. Commun. 415 (2011) 509–514.
[34] J.F. Vanhauwe, K. Josson, W.H. Luyten, A.J. Driessen, J.E. Leysen, G-protein sensitivity
of ligand binding to human dopamine D(2) and D(3) receptors expressed in
Escherichia coli: clues for a constrained D(3) receptor structure, J. Pharmacol. Exp.
Ther. 295 (2000) 274–283.
[35] E.H. Schneider, D. Schnell, D. Papa, R. Seifert, High constitutive activity and a G
protein-independent high-afﬁnity state of the human histamine H4 receptor,
Biochemistry 48 (2009) 1424–1438.
[36] T. Chikai, R. Oishi, K. Saeki, Microdialysis study of the effects of sedative drugs on
extracellular histamine in the striatum of freely moving rats, J. Pharmacol. Exp.
Ther. 266 (1993) 1277–1281.
[37] P. Cumming, G. Damsma, H.C. Fibiger, S.R. Vincent, Characterization of extracellular
histamine in the striatumand bed nucleus of the stria terminalis of the rat: an in vivo
microdialysis study, J. Neurochem. 56 (1991) 1797–1803.
[38] B. Washington, J.B. Shaw, J. Li, B. Fisher, J. Gwathmey, In vivo histamine release from
brain cortex: the effects ofmodulating cellular and extracellular sodiumand calcium
channels, Eur. J. Pharmacol. 407 (2000) 117–122.
[39] T.P. Kenakin, The classiﬁcation of drugs and drug receptors in isolated tissues,
Pharmacol. Rev. 36 (1984) 165–222.
[40] F. Gbahou, L. Vincent, M. Humbert-Claude, J. Tardivel-Lacombe, C. Chabret, J.M.
Arrang, Compared pharmacology of human histamine H3 and H4 receptors:
structure–activity relationships of histamine derivatives, Br. J. Pharmacol. 147
(2006) 744–754.
[41] P. Werner, N. Hussy, G. Buell, K.A. Jones, R.A. North, D2, D3, and D4 dopamine re-
ceptors couple to G protein-regulated potassium channels in Xenopus oocytes,
Mol. Pharmacol. 49 (1996) 656–661.
[42] H.E. Schneider, D. Schnell, A. Strasser, S. Dove, R. Seifert, Impact of the DRY
motif and the missing “ionic lock” on constitutive activity and G-protein coupling
of the human histamine H4receptor, J. Pharmacol. Exp. Ther. 333 (2010) 382–392.
[43] L. Hein, J.D. Altman, B.K. Kobilka, Two functionally distinct alpha2-adrenergic receptors
regulate sympathetic neurotransmission, Nature 402 (1999) 181–184.
